AMT Announces Positive Interim Clinical Data on its Lead Produ... (withfat accumulations in skin or retina ...)

AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011

Date:5/29/2008

with fat accumulations in skin or retina, these accumulations disappeared or were reduced. All patients reported gain of energy. In the two patients that had diabetes, a reduction of insulin resistance was observed, leading to a reduction of their diabetic medication. One patient experienced a pancreatitis episode immediately after injection, when fat levels in the blood were still high. But to date no other episodes of pancreatitis have been observed in patients treated with Glybera(R) in this study.

Upon completion of the study the results will be part of the filing dossier for the marketing approval of Glybera(R).

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unkno
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

(Date:12/16/2009)... A new application developed by ... review of specialty pharmaceuticals has increased health plan ... while reducing costs. ,, AIM, a leading diagnostic ... plan clients representing over 35 million consumers and ... WLP ), adapted the successful clinical and ...

(Date:12/16/2009)... at,deCODE genetics, Inc. (Nasdaq: DCGN ) publish in ... a common single-letter variant in the sequence of,the ... susceptibility to type 2,diabetes (T2D). The impact of ... unusual:,if an individual inherits it from their father, ... 30% compared to those who inherit the non ...

(Date:12/16/2009)... December 16 International, well-known,scientific ... of GFT505 (80 mg/day),data presented as ... expert scientists and clinicians critically reviewed ... role of generic lipid-modifying,treatments, fenofibrate and ... commonly observed in patients with metabolic ...

Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4 International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2 International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3 Domain Registration Corp Announces Name Change to BioPharm Asia Inc 52208 1 Domain Registration Corp Announces Name Change to BioPharm Asia Inc 52208 2 Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52205 1 Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52205 2 Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52205 3 Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52205 4 Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52205 5 BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52202 1 BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52202 2 BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52202 3

[0] American Imaging Management's New Specialty Drug Program Delivers Immediate Results [0] deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin [0] International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia

... Terumo Heart, Inc. announced,today approval from the Institutional ... move forward with the DuraHeart(TM) Left Ventricular Assist,System ... Francis Pagani, M.D., Ph.D., Director of the Adult ... of,Michigan, will serve as the National Co-Principal Investigator ...

... Congress Focus Attention on a New ... ... Frontiers, Inc.,today announced that two studies reporting positive findings about ... Cardiostim World Congress, a premier meeting for physicians that,treat cardiac ...

Other Medicine Technology:Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial 2 Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times 2 Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times 3

Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times

(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...

(Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...

(Date:12/16/2009)... and Encourage Access to Quality, Cost-Effective Care , ... ... Congress have debated the best ways to rein in runaway costs ... An important part of the ongoing discussion includes how to ... providers besides doctors of medicine (MDs) or osteopathy (DOs). In ...

(Date:12/16/2009)... MassBio promote Massachusetts companies through annual marketing campaign , ... ... -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , ,Genetown is sponsored by MassBio and ... industries. The campaign places each entity’s brand on an ...

(Date:12/16/2009)... Inc., developers of the AcceleDent System , ... announced Alison Davies as its new Director of ... spent the last fourteen years of her professional ... nine years as a senior manager with ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO ) ,, ...

Breaking Medicine News(10 mins):Health News:House Creates New Cancer Research Program 2 Health News:House Creates New Cancer Research Program 3 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:Thriving Bioscience Region Leaves Its Mark 2 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4

[0] House Creates New Cancer Research Program [1] Lung cancer and melanoma laid bare [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] Thriving Bioscience Region Leaves Its Mark [1] Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom

... When someone speaks to you, do you see what they ... something we hear, but recent studies suggest that we use ... brain treats speech as something we hear, see and even ... Psychological Science , a journal of the Association for Psychological ...

... night,s sleep can do wonders for yourself and ... few more zzz,s in bed can increase the ... from the Better Sleep Council at: http://inr.mediaseed.tv/oneClip_C/?feed=7E0KmviyT9LW2v0hfAgy3p72EXQ2__rd ... and photos for free and unrestricted use at ...

... will enable more time for direct resident ... and increase staff satisfactionPITTSBURGH, Feb. 11 ... Care Partners Management Group (Preferred Care) headquartered ... care in two of its managed skilled ...

... to Move Policymakers to "Thoughtful Dialogue"WASHINGTON, Feb. 11 ... debate the merits of the Medicare Durable Medical ... program, home oxygen leaders call on legislators to ... having on beneficiary services and much needed service-oriented ...

... particularly in the areas of community development, health and ... the economy did not deter the trustees of The ... its fourth-quarter board meeting in December, making the quarter, ... as a whole, the most generous in the foundation,s ...

... Ariz., Feb. 11 eSoles(R) Custom Footbeds, the,world,s leading ... footbeds, today announced that it is an official sponsor ... the 2009 Amgen(R) Tour of,California road cycling race, which ... to Escondido, February 14 - 22, 2009. , ...

Read my lips: Using multiple senses in speech perception AUDIO from Medialink and the Better Sleep Council: Wake Up Your Relationship With Good Sleep This Valentine's Day Preferred Care Partners Management Group Deploys Voice-Assisted Care As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 eSoles Custom Footbeds Sponsors OUCH Pro Cycling Team in America's Largest Road Cycling Race

Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Most popular size or model....

Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....

Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish....

Straight shafts with 1 x 2 teeth. Wide serrated handle with polished finish....

Medicine Products:

Storz Bonn Suturing Forceps McPherson Straight Suturing-Corneal Forceps McCullough Suturing Forceps Sauer Suturing Forceps

AMT Announces Positive Interim Clinical Data on its Lead Produ...(withfat accumulations in skin or retina ...),Health